Jane W. Newburger

Improving neurodevelopmental outcomes in children with congenital heart disease: protocol for a randomised controlled trial of working memory training

D. Wypij, J. Newburger, D. Bellinger, 2019, BMJ Open.

Neurodevelopmental Outcomes in Children With Congenital Heart Disease: Evaluation and Management A Scientific Statement From the American Heart Association

J. Newburger, J. Gaynor, Sabrina E. Smith, 2012, Circulation.

Neurodevelopmental Outcomes for Individuals With Congenital Heart Disease: Updates in Neuroprotection, Risk-Stratification, Evaluation, and Management: A Scientific Statement From the American Heart Association

A. Lisanti, S. Peyvandi, J. Anixt, 2024, Circulation.

De novo variants in FRYL are associated with developmental delay, intellectual disability, and dysmorphic features.

Denise G. Lanza, Jason D. Heaney, J. Posey, 2024, American journal of human genetics.

Meta-regression of sulcal patterns, clinical and environmental factors on neurodevelopmental outcomes in participants with multiple CHD types.

D. Wypij, C. Rollins, H. Yun, 2024, Cerebral cortex.

Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.

E. Orgel, J. Hochberg, A. Esbenshade, 2023, The Lancet. Haematology.

Neuroimaging and Neurodevelopmental Outcomes Among Individuals With Complex Congenital Heart Disease: JACC State-of-the-Art Review.

V. Rajagopalan, Nadine A. Kasparian, Jane W. Newburger, 2023, Journal of the American College of Cardiology.